Changes in Hong Kong stocks | Dongyang Pharmaceutical (06887) has opened more than 6% of its self-developed glycine insulin injections and has been approved for listing in the US

Zhitongcaijing · 2d ago

The Zhitong Finance App learned that Dongyang Pharmaceutical (06887) opened more than 6% higher. As of press release, it had risen 6.43% to HK$29.8, with a turnover of HK$4261,000.

According to the news, on July 17, Dongyang Pharmaceutical announced that the group's self-developed glycine insulin injection has obtained approval from the US Food and Drug Administration for marketing. This product is scheduled to be shipped in the near future. After the product is successfully shipped, the Group expects to launch the official commercialization of the product in the US market in due course. This milestone will further expand the company's overseas revenue, enhance the company's global competitiveness in hypoglycemic drugs, and accelerate the implementation of the strategic layout of internationalization and industrialization.